Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant Mesothelioma

NCT00027703 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

106

Enrollment

NIH

Sponsor class

Conditions

Advanced Malignant Mesothelioma
Epithelial Mesothelioma
Localized Malignant Mesothelioma
Recurrent Malignant Mesothelioma
Sarcomatous Mesothelioma

Interventions

DRUG: gemcitabine hydrochloride
DRUG: cisplatin
BIOLOGICAL: bevacizumab
OTHER: placebo
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)